Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.
Identifieur interne : 001D13 ( PubMed/Corpus ); précédent : 001D12; suivant : 001D14Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.
Auteurs : Anastasia N. Vlasova ; Xinsheng Zhang ; Mustafa Hasoksuz ; Hadya S. Nagesha ; Lia M. Haynes ; Ying Fang ; Shan Lu ; Linda J. SaifSource :
- Journal of virology [ 1098-5514 ] ; 2007.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antigens, Viral (blood), Antigens, Viral (immunology), Cats, Cattle, Cell Line, Coronavirus (classification), Coronavirus (immunology), Coronavirus Infections (veterinary), Coronavirus Infections (virology), Cross Reactions, Dogs, Guinea Pigs, Humans, Immune Sera (immunology), Nucleocapsid Proteins (chemistry), Nucleocapsid Proteins (genetics), Nucleocapsid Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (virology).
- MESH :
- chemical , blood : Antibodies, Viral, Antigens, Viral.
- chemical , chemistry : Nucleocapsid Proteins.
- chemical , genetics : Nucleocapsid Proteins.
- chemical , immunology : Antibodies, Viral, Antigens, Viral, Immune Sera, Nucleocapsid Proteins.
- classification : Coronavirus.
- immunology : Coronavirus, SARS Virus.
- veterinary : Coronavirus Infections.
- virology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Animals, Cats, Cattle, Cell Line, Cross Reactions, Dogs, Guinea Pigs, Humans.
Abstract
In 2002, severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged in humans, causing a global epidemic. By phylogenetic analysis, SARS-CoV is distinct from known CoVs and most closely related to group 2 CoVs. However, no antigenic cross-reactivity between SARS-CoV and known CoVs was conclusively and consistently demonstrated except for group 1 animal CoVs. We analyzed this cross-reactivity by an enzyme-linked immunosorbent assay (ELISA) and Western blot analysis using specific antisera to animal CoVs and SARS-CoV and SARS patient convalescent-phase or negative sera. Moderate two-way cross-reactivity between SARS-CoV and porcine CoVs (transmissible gastroenteritis CoV [TGEV] and porcine respiratory CoV [PRCV]) was mediated through the N but not the spike protein, whereas weaker cross-reactivity occurred with feline (feline infectious peritonitis virus) and canine CoVs. Using Escherichia coli-expressed recombinant SARS-CoV N protein and fragments, the cross-reactive region was localized between amino acids (aa) 120 to 208. The N-protein fragments comprising aa 360 to 412 and aa 1 to 213 reacted specifically with SARS convalescent-phase sera but not with negative human sera in ELISA; the fragment comprising aa 1 to 213 cross-reacted with antisera to animal CoVs, whereas the fragment comprising aa 360 to 412 did not cross-react and could be a potential candidate for SARS diagnosis. Particularly noteworthy, a single substitution at aa 120 of PRCV N protein diminished the cross-reactivity. We also demonstrated that the cross-reactivity is not universal for all group 1 CoVs, because HCoV-NL63 did not cross-react with SARS-CoV. One-way cross-reactivity of HCoV-NL63 with group 1 CoVs was localized to aa 1 to 39 and at least one other antigenic site in the N-protein C terminus, differing from the cross-reactive region identified in SARS-CoV N protein. The observed cross-reactivity is not a consequence of a higher level of amino acid identity between SARS-CoV and porcine CoV nucleoproteins, because sequence comparisons indicated that SARS-CoV N protein has amino acid identity similar to that of infectious bronchitis virus N protein and shares a higher level of identity with bovine CoV N protein within the cross-reactive region. The TGEV and SARS-CoV N proteins are RNA chaperons with long disordered regions. We speculate that during natural infection, antibodies target similar short antigenic sites within the N proteins of SARS-CoV and porcine group 1 CoVs that are exposed to an immune response. Identification of the cross-reactive and non-cross-reactive N-protein regions allows development of SARS-CoV-specific antibody assays for screening animal and human sera.
DOI: 10.1128/JVI.01169-07
PubMed: 17913799
Links to Exploration step
pubmed:17913799Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.</title>
<author><name sortKey="Vlasova, Anastasia N" sort="Vlasova, Anastasia N" uniqKey="Vlasova A" first="Anastasia N" last="Vlasova">Anastasia N. Vlasova</name>
<affiliation><nlm:affiliation>Food Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agricultural Research and Development Center, The Ohio State University, 1680 Madison Avenue, Wooster, OH 44691-4096, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Xinsheng" sort="Zhang, Xinsheng" uniqKey="Zhang X" first="Xinsheng" last="Zhang">Xinsheng Zhang</name>
</author>
<author><name sortKey="Hasoksuz, Mustafa" sort="Hasoksuz, Mustafa" uniqKey="Hasoksuz M" first="Mustafa" last="Hasoksuz">Mustafa Hasoksuz</name>
</author>
<author><name sortKey="Nagesha, Hadya S" sort="Nagesha, Hadya S" uniqKey="Nagesha H" first="Hadya S" last="Nagesha">Hadya S. Nagesha</name>
</author>
<author><name sortKey="Haynes, Lia M" sort="Haynes, Lia M" uniqKey="Haynes L" first="Lia M" last="Haynes">Lia M. Haynes</name>
</author>
<author><name sortKey="Fang, Ying" sort="Fang, Ying" uniqKey="Fang Y" first="Ying" last="Fang">Ying Fang</name>
</author>
<author><name sortKey="Lu, Shan" sort="Lu, Shan" uniqKey="Lu S" first="Shan" last="Lu">Shan Lu</name>
</author>
<author><name sortKey="Saif, Linda J" sort="Saif, Linda J" uniqKey="Saif L" first="Linda J" last="Saif">Linda J. Saif</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17913799</idno>
<idno type="pmid">17913799</idno>
<idno type="doi">10.1128/JVI.01169-07</idno>
<idno type="wicri:Area/PubMed/Corpus">001D13</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D13</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.</title>
<author><name sortKey="Vlasova, Anastasia N" sort="Vlasova, Anastasia N" uniqKey="Vlasova A" first="Anastasia N" last="Vlasova">Anastasia N. Vlasova</name>
<affiliation><nlm:affiliation>Food Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agricultural Research and Development Center, The Ohio State University, 1680 Madison Avenue, Wooster, OH 44691-4096, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Xinsheng" sort="Zhang, Xinsheng" uniqKey="Zhang X" first="Xinsheng" last="Zhang">Xinsheng Zhang</name>
</author>
<author><name sortKey="Hasoksuz, Mustafa" sort="Hasoksuz, Mustafa" uniqKey="Hasoksuz M" first="Mustafa" last="Hasoksuz">Mustafa Hasoksuz</name>
</author>
<author><name sortKey="Nagesha, Hadya S" sort="Nagesha, Hadya S" uniqKey="Nagesha H" first="Hadya S" last="Nagesha">Hadya S. Nagesha</name>
</author>
<author><name sortKey="Haynes, Lia M" sort="Haynes, Lia M" uniqKey="Haynes L" first="Lia M" last="Haynes">Lia M. Haynes</name>
</author>
<author><name sortKey="Fang, Ying" sort="Fang, Ying" uniqKey="Fang Y" first="Ying" last="Fang">Ying Fang</name>
</author>
<author><name sortKey="Lu, Shan" sort="Lu, Shan" uniqKey="Lu S" first="Shan" last="Lu">Shan Lu</name>
</author>
<author><name sortKey="Saif, Linda J" sort="Saif, Linda J" uniqKey="Saif L" first="Linda J" last="Saif">Linda J. Saif</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antigens, Viral (blood)</term>
<term>Antigens, Viral (immunology)</term>
<term>Cats</term>
<term>Cattle</term>
<term>Cell Line</term>
<term>Coronavirus (classification)</term>
<term>Coronavirus (immunology)</term>
<term>Coronavirus Infections (veterinary)</term>
<term>Coronavirus Infections (virology)</term>
<term>Cross Reactions</term>
<term>Dogs</term>
<term>Guinea Pigs</term>
<term>Humans</term>
<term>Immune Sera (immunology)</term>
<term>Nucleocapsid Proteins (chemistry)</term>
<term>Nucleocapsid Proteins (genetics)</term>
<term>Nucleocapsid Proteins (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Antigens, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Nucleocapsid Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nucleocapsid Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Antigens, Viral</term>
<term>Immune Sera</term>
<term>Nucleocapsid Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="veterinary" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cats</term>
<term>Cattle</term>
<term>Cell Line</term>
<term>Cross Reactions</term>
<term>Dogs</term>
<term>Guinea Pigs</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 2002, severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged in humans, causing a global epidemic. By phylogenetic analysis, SARS-CoV is distinct from known CoVs and most closely related to group 2 CoVs. However, no antigenic cross-reactivity between SARS-CoV and known CoVs was conclusively and consistently demonstrated except for group 1 animal CoVs. We analyzed this cross-reactivity by an enzyme-linked immunosorbent assay (ELISA) and Western blot analysis using specific antisera to animal CoVs and SARS-CoV and SARS patient convalescent-phase or negative sera. Moderate two-way cross-reactivity between SARS-CoV and porcine CoVs (transmissible gastroenteritis CoV [TGEV] and porcine respiratory CoV [PRCV]) was mediated through the N but not the spike protein, whereas weaker cross-reactivity occurred with feline (feline infectious peritonitis virus) and canine CoVs. Using Escherichia coli-expressed recombinant SARS-CoV N protein and fragments, the cross-reactive region was localized between amino acids (aa) 120 to 208. The N-protein fragments comprising aa 360 to 412 and aa 1 to 213 reacted specifically with SARS convalescent-phase sera but not with negative human sera in ELISA; the fragment comprising aa 1 to 213 cross-reacted with antisera to animal CoVs, whereas the fragment comprising aa 360 to 412 did not cross-react and could be a potential candidate for SARS diagnosis. Particularly noteworthy, a single substitution at aa 120 of PRCV N protein diminished the cross-reactivity. We also demonstrated that the cross-reactivity is not universal for all group 1 CoVs, because HCoV-NL63 did not cross-react with SARS-CoV. One-way cross-reactivity of HCoV-NL63 with group 1 CoVs was localized to aa 1 to 39 and at least one other antigenic site in the N-protein C terminus, differing from the cross-reactive region identified in SARS-CoV N protein. The observed cross-reactivity is not a consequence of a higher level of amino acid identity between SARS-CoV and porcine CoV nucleoproteins, because sequence comparisons indicated that SARS-CoV N protein has amino acid identity similar to that of infectious bronchitis virus N protein and shares a higher level of identity with bovine CoV N protein within the cross-reactive region. The TGEV and SARS-CoV N proteins are RNA chaperons with long disordered regions. We speculate that during natural infection, antibodies target similar short antigenic sites within the N proteins of SARS-CoV and porcine group 1 CoVs that are exposed to an immune response. Identification of the cross-reactive and non-cross-reactive N-protein regions allows development of SARS-CoV-specific antibody assays for screening animal and human sera.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17913799</PMID>
<DateCompleted><Year>2007</Year>
<Month>12</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>81</Volume>
<Issue>24</Issue>
<PubDate><Year>2007</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.</ArticleTitle>
<Pagination><MedlinePgn>13365-77</MedlinePgn>
</Pagination>
<Abstract><AbstractText>In 2002, severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged in humans, causing a global epidemic. By phylogenetic analysis, SARS-CoV is distinct from known CoVs and most closely related to group 2 CoVs. However, no antigenic cross-reactivity between SARS-CoV and known CoVs was conclusively and consistently demonstrated except for group 1 animal CoVs. We analyzed this cross-reactivity by an enzyme-linked immunosorbent assay (ELISA) and Western blot analysis using specific antisera to animal CoVs and SARS-CoV and SARS patient convalescent-phase or negative sera. Moderate two-way cross-reactivity between SARS-CoV and porcine CoVs (transmissible gastroenteritis CoV [TGEV] and porcine respiratory CoV [PRCV]) was mediated through the N but not the spike protein, whereas weaker cross-reactivity occurred with feline (feline infectious peritonitis virus) and canine CoVs. Using Escherichia coli-expressed recombinant SARS-CoV N protein and fragments, the cross-reactive region was localized between amino acids (aa) 120 to 208. The N-protein fragments comprising aa 360 to 412 and aa 1 to 213 reacted specifically with SARS convalescent-phase sera but not with negative human sera in ELISA; the fragment comprising aa 1 to 213 cross-reacted with antisera to animal CoVs, whereas the fragment comprising aa 360 to 412 did not cross-react and could be a potential candidate for SARS diagnosis. Particularly noteworthy, a single substitution at aa 120 of PRCV N protein diminished the cross-reactivity. We also demonstrated that the cross-reactivity is not universal for all group 1 CoVs, because HCoV-NL63 did not cross-react with SARS-CoV. One-way cross-reactivity of HCoV-NL63 with group 1 CoVs was localized to aa 1 to 39 and at least one other antigenic site in the N-protein C terminus, differing from the cross-reactive region identified in SARS-CoV N protein. The observed cross-reactivity is not a consequence of a higher level of amino acid identity between SARS-CoV and porcine CoV nucleoproteins, because sequence comparisons indicated that SARS-CoV N protein has amino acid identity similar to that of infectious bronchitis virus N protein and shares a higher level of identity with bovine CoV N protein within the cross-reactive region. The TGEV and SARS-CoV N proteins are RNA chaperons with long disordered regions. We speculate that during natural infection, antibodies target similar short antigenic sites within the N proteins of SARS-CoV and porcine group 1 CoVs that are exposed to an immune response. Identification of the cross-reactive and non-cross-reactive N-protein regions allows development of SARS-CoV-specific antibody assays for screening animal and human sera.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vlasova</LastName>
<ForeName>Anastasia N</ForeName>
<Initials>AN</Initials>
<AffiliationInfo><Affiliation>Food Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agricultural Research and Development Center, The Ohio State University, 1680 Madison Avenue, Wooster, OH 44691-4096, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Xinsheng</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hasoksuz</LastName>
<ForeName>Mustafa</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nagesha</LastName>
<ForeName>Hadya S</ForeName>
<Initials>HS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Haynes</LastName>
<ForeName>Lia M</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fang</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Shan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Saif</LastName>
<ForeName>Linda J</ForeName>
<Initials>LJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R21 AI062763</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2007</Year>
<Month>10</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002415" MajorTopicYN="N">Cats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000662" MajorTopicYN="Y">veterinary</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>10</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>12</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>10</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17913799</ArticleId>
<ArticleId IdType="pii">JVI.01169-07</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.01169-07</ArticleId>
<ArticleId IdType="pmc">PMC2168854</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 May;42(5):2351-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15131233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Genet Evol. 2003 Sep;3(3):219-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14522185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2003 Sep 20;4:43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14499005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Oct 30;425(6961):915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14586458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Chem. 2003 Dec;49(12):1989-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14633869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jan;78(1):76-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14671089</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2004 Mar;149(3):621-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14991447</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Diagn Lab Immunol. 2004 Mar;11(2):362-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15013989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2004 May 1;189(9):1676-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15116304</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jul;78(13):6938-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2004 Jul 15;190(2):379-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15216476</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Vet Res. 1999 Oct;60(10):1227-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10791935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Diagn Lab Immunol. 2001 Mar;8(2):297-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11238212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Avian Dis. 2001 Jan-Mar;45(1):157-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11332477</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Aug;78(15):7863-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15254158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Jul;10(7):1293-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15324552</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 Sep 15;173(6):4050-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15356154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Oct;78(20):11401-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15452262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Nov;78(22):12557-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 1976 May 7;72:248-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 1988;101(3-4):221-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2845894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1995 Dec;33(12):3264-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8586714</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1997 Nov;35(11):2937-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9350763</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 Nov;42(11):5309-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15528730</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Nov;10(11):1947-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15550204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Jan;79(1):503-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15596843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genomics Proteomics Bioinformatics. 2003 Aug;1(3):198-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15629032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Feb;79(4):2620-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15681462</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Sci Tech. 2004 Aug;23(2):643-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15702725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2005 Mar;11(3):446-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15757562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2005 Apr 11;579(10):2130-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15811330</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2005 Jun 15;191(12):2033-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15897988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2005 Sep;128(1-2):21-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15885812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Sep;79(18):11892-900</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16140765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2005;5:73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16171519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2004 Aug;1(4):304-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16225774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Diagn Lab Immunol. 2005 Nov;12(11):1317-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16275947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Feb 13;24(7):1028-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16388880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2005 Dec;11(12):1860-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16485471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2006 Mar;13(3):409-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16522785</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol. 2006 Feb;44(1):83-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16554722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Apr 12;24(16):3100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 May;80(9):4211-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16611880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2006;581:153-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17037523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2007 Jan 20;357(2):215-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16979208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2006;3:106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17194306</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2007 Feb 20;358(2):424-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17023013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Mol Med. 2003 Aug;9(8):325-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12928032</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001D13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:17913799 |texte= Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17913799" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |